Shanghai Fosun Pharmaceutical Group Co., Ltd. (600196)

Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., established in 1994 and headquartered in Shanghai, China, operates extensively in the pharmaceutical sector, presenting a significant presence both domestically in Mainland China and on an international scale. The company has dedicated itself to the development, manufacturing, and distribution of a diverse range of pharmaceutical products, delving into the realms of advanced therapy and medication to tackle a variety of diseases and conditions. Furthermore, Shanghai Fosun Pharmaceutical extends its reach to the import and export of medical devices, offering related consulting services, engaging in healthcare services, and the retail and wholesale distribution of medicines. With a strong foundation in investment management, the company's business portfolio encompasses a wide spectrum within the healthcare and pharmaceutical industries.

Products and Services

The company boasts an impressive line-up in its pipeline, spanning different phases of drug development from phase 1 through phase 3:

• HLX15: A recombinant anti-CD38 human monoclonal antibody injection designed for the treatment of multiple myeloma.
• HLX13: An anti-CTLA-4 human monoclonal antibody targeting several types of cancer including melanoma and renal cell carcinoma.
• SZEY-2108: Focused on combating carbapenem-resistant Enterobacteriaceae (CRE) infections.
• XH-S003: Aimed at addressing IgA nephropathy and other glomerular diseases.
• HLX43: An antibody-drug conjugate in development for the treatment of metastatic solid tumors.
• XS-03: Targeted therapy for RAS-mutated advanced solid tumors.
• OP0595 (Nacubactam): Designed to treat infections caused by aerobic gram-negative bacteria.
• XH-S002: Under development for treating ischemic stroke and transient ischemic attack.
• Phase 2 Pipeline Products:
• HLX26: Anti-LAG-3 humanized monoclonal antibody injection being explored for the treatment of metastatic colorectal cancer.
• FCN-338: In research for the treatment of myeloid malignancies.
• FCN-159: Under development for both the treatment of Langerhans cell histiocytosis and neurofibromatosis.
• HLX208: A BRAF V600E inhibitor being tested for non-small cell lung cancer.
• Phase 3 Pipeline Products:
• FS-1502: A HER2 humanized monoclonal antibody-monomethyl auristatin F injection for HER2-positive locally advanced or metastatic breast cancer.
• ET-26: Investigated for the use in general anesthesia, this is a methoxyetomidate hydrochloride.

In addition, Shanghai Fosun Pharmaceutical engages in:

• Import and Export of Medical Equipment: Providing top-tier medical devices and relevant consulting services globally.
• Healthcare Service: Offering medical services and diagnostics products.
• Investment Management: Overseeing investments across various sectors within the pharmaceutical and healthcare industries.
• Retail and Wholesale Distribution: Distributing medicines both directly to consumers and to other businesses within the pharmaceutical sector.